JP2019537619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537619A5 JP2019537619A5 JP2019538088A JP2019538088A JP2019537619A5 JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5 JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- antibody
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400589P | 2016-09-27 | 2016-09-27 | |
| US62/400,589 | 2016-09-27 | ||
| US201662406727P | 2016-10-11 | 2016-10-11 | |
| US62/406,727 | 2016-10-11 | ||
| US201762480994P | 2017-04-03 | 2017-04-03 | |
| US62/480,994 | 2017-04-03 | ||
| US201762507580P | 2017-05-17 | 2017-05-17 | |
| US62/507,580 | 2017-05-17 | ||
| PCT/US2017/053370 WO2018064013A1 (en) | 2016-09-27 | 2017-09-26 | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537619A JP2019537619A (ja) | 2019-12-26 |
| JP2019537619A5 true JP2019537619A5 (enExample) | 2020-11-12 |
Family
ID=66538296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538088A Pending JP2019537619A (ja) | 2016-09-27 | 2017-09-26 | β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3519827A1 (enExample) |
| JP (1) | JP2019537619A (enExample) |
| KR (1) | KR20190057303A (enExample) |
| CN (1) | CN109863402A (enExample) |
| AU (1) | AU2017334698A1 (enExample) |
| CA (1) | CA3037008A1 (enExample) |
| MX (1) | MX2019003569A (enExample) |
| WO (1) | WO2018064013A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200020662A (ko) * | 2017-04-03 | 2020-02-26 | 온콜로지, 인크. | 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법 |
| JP2021534393A (ja) * | 2018-08-13 | 2021-12-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 疑似インビボ条件での治療用タンパク質の選択 |
| US20220363762A1 (en) * | 2020-05-12 | 2022-11-17 | Astrazeneca Ab | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| CN114716547B (zh) * | 2022-05-18 | 2023-11-21 | 珠海丽禾医疗诊断产品有限公司 | 一种包括抗原结合结构域的结合蛋白及其生产方法和应用 |
| WO2024065243A1 (en) * | 2022-09-28 | 2024-04-04 | University Of Macau | Drug for treatment of breast cancer and application thereof |
| CN119555937B (zh) * | 2025-01-26 | 2025-05-20 | 杭州奥泰生物技术股份有限公司 | 一种犬虫媒病五联抗体检测卡及其制备方法和试剂盒 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| AU771224B2 (en) | 1998-07-13 | 2004-03-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| AU2012201537B2 (en) * | 2002-07-15 | 2014-06-05 | Board Of Regents, The University Of Texas System | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
| US7572448B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| CN101146826A (zh) | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2015131153A1 (en) | 2014-02-27 | 2015-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions for isolating exosomes |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
-
2017
- 2017-09-26 JP JP2019538088A patent/JP2019537619A/ja active Pending
- 2017-09-26 CA CA3037008A patent/CA3037008A1/en not_active Abandoned
- 2017-09-26 CN CN201780058161.8A patent/CN109863402A/zh active Pending
- 2017-09-26 WO PCT/US2017/053370 patent/WO2018064013A1/en not_active Ceased
- 2017-09-26 MX MX2019003569A patent/MX2019003569A/es unknown
- 2017-09-26 AU AU2017334698A patent/AU2017334698A1/en not_active Abandoned
- 2017-09-26 EP EP17791768.9A patent/EP3519827A1/en not_active Withdrawn
- 2017-09-26 KR KR1020197008828A patent/KR20190057303A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hidalgo et al. | First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors | |
| Wu et al. | Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway | |
| Otvos Jr et al. | Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer | |
| Wu et al. | Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF (V600E) mutant cancer cells | |
| ES2734673T3 (es) | Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas | |
| Nikolaou et al. | The role of neurotensin and its receptors in non-gastrointestinal cancers: A review | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| AU2018287519A1 (en) | Il-1beta binding antibodies for use in treating cancer | |
| JP2021510697A5 (enExample) | ||
| JP6381735B2 (ja) | 併用抗がん剤の感受性判定マーカー | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| CN117425515A (zh) | 用交变电场和曲妥珠单抗的组合进行治疗的组合物和方法 | |
| Park et al. | GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer | |
| CN112469391A (zh) | 包括chk1抑制剂的癌症的治疗方法 | |
| Taylor et al. | Anti-angiogenic therapy in high-grade glioma (treatment and toxicity) | |
| JP2023156343A (ja) | がん幹細胞の低減におけるｗｎｔ５ａペプチド | |
| JP7369378B2 (ja) | 抗がん剤及びがんを治療するための医薬組成物 | |
| JP2017535548A5 (enExample) | ||
| Yuan et al. | Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma | |
| KR20230004590A (ko) | 다형성 교모세포종에서의 abcb5 표적화 | |
| KR20250169564A (ko) | 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정 | |
| Huhtala et al. | Biodistribution and antitumor effect of Cetuximab-targeted lentivirus | |
| Simeone et al. | A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600 BRAF mutation | |
| US9566334B2 (en) | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder | |
| US20210154262A1 (en) | Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer |